Target Name: CDC42
NCBI ID: G998
Review Report on CDC42 Target / Biomarker Content of Review Report on CDC42 Target / Biomarker
CDC42
Other Name(s): G25K | dJ224A6.1.1 (cell division cycle 42 (GTP-binding protein, 25kD)) | G25K GTP-binding protein | growth-regulating protein | cell division control protein 42 homolog | Cell division control protein 42 homolog (isoform 2) | Cell division cycle 42, transcript variant 3 | TKS | Cell division control protein 42 homolog (isoform 1) | CDC42Hs | Growth-regulating protein | GTP-binding protein, 25kD | CDC42 variant 3 | CDC42 variant 1 | Cell division cycle 42 (GTP binding protein, 25kD) | GTP binding protein, 25kDa | CDC42_HUMAN | cell division cycle 42 | small GTP binding protein CDC42 | Cell division cycle 42, transcript variant 2 | Cell division control protein 42 homolog | Cell division cycle 42, transcript variant 1 | CDC42 variant 2 | Small GTP binding protein | dJ224A6.1.2 (cell division cycle 42 (GTP-binding protein, 25kD))

CDC42 (G25K) as a Drug Target and Biomarker: A Promising Approach for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people worldwide have chronic pain, with 20% of the population reporting moderate to severe chronic pain. Chronic pain can be caused by various conditions, such as osteoarthritis, fibromyalgia, cancer, and neurodegenerative diseases, leading to significant morbidity and economic costs.

The search for new treatments for chronic pain has led to the development of various compounds, including drugs and biomarkers. One of these compounds is CDC42 (G25K), a small molecule inhibitor of the enzyme G25K, which is involved in the synthesis of a protein called Runx1a. In this article, we will discuss CDC42 (G25K) as a drug target and biomarker for the treatment of chronic pain.

CDC42 (G25K) as a Drug Target

CDC42 (G25K) is a small molecule inhibitor of the enzyme G25K, which is involved in the synthesis of the protein Runx1a. The N-terminal domain of CDC42 (G25K) contains a unique electrostatic potential that interacts with the G25K active site, leading to a 150-fold increase in the inhibition of G25K-mediated protein synthesis.

Runx1a is a protein that plays a crucial role in the development and maintenance of tissues, including muscles, bones, and tissues. It is involved in several cellular processes, including cell growth, differentiation, and inflammation. Studies have shown that Runx1a is involved in the development of chronic pain conditions, such as osteoarthritis, cancer, and neurodegenerative diseases.

In addition to its role in the development of chronic pain conditions,Runx1a is also involved in the regulation of pain perception. It has been shown to play a role in the modulation of pain sensitivity and the production of pain modulatory neurotransmitters, such as nitric oxide and opioids.

CDC42 (G25K) as a Biomarker

CDC42 (G25K) has also been shown to be a potential biomarker for the evaluation of chronic pain. The G25K enzyme is involved in the synthesis of several proteins, including Runx1a, which is involved in the development and maintenance of tissues. Therefore, the levels of G25K and Runx1a can be used as biomarkers for the assessment of chronic pain.

Studies have shown that the levels of G25K and Runx1a are significantly increased in individuals with chronic pain conditions, such as osteoarthritis, cancer, and neurodegenerative diseases. Additionally, changes in the levels of G25K and Runx1a have been observed in individuals who have undergone surgical interventions for chronic pain conditions.

Conclusion

In conclusion, CDC42 (G25K) has shown promise as a drug target and biomarker for the treatment of chronic pain. Its ability to inhibit the activity of G25K and modulate pain perception makes it a promising compound for the development of new treatments for chronic pain conditions. Further research is needed to fully understand the mechanisms of CDC42 (G25K) and its potential as a therapeutic agent.

Protein Name: Cell Division Cycle 42

Functions: Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses. Involved in epithelial cell polarization processes. Regulates the bipolar attachment of spindle microtubules to kinetochores before chromosome congression in metaphase (PubMed:15642749). Regulates cell migration (PubMed:17038317). In neurons, plays a role in the extension and maintenance of the formation of filopodia, thin and actin-rich surface projections (PubMed:14978216). Required for DOCK10-mediated spine formation in Purkinje cells and hippocampal neurons. In podocytes, facilitates filopodia and podosomes formation upon DOCK11-activation (PubMed:33523862). Upon activation by CaMKII, modulates dendritic spine structural plasticity by relaying CaMKII transient activation to synapse-specific, long-term signaling (By similarity). Also plays a role in phagocytosis through organization of the F-actin cytoskeleton associated with forming phagocytic cups (PubMed:26465210)

The "CDC42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C